Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: A stopped multicentre randomised trial

Lancet

Volumn 348, Issue 9027, 1996, Pages 563-566

  Thatcher, N ^b   Clark, P I ^b   Girling, David J ^a   Hopwood, P ^b   Widdy, S T ^b   Stephens, R J ^b   Bailey, A J ^b   Machin, D ^b  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ALKALOID; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; VINCRISTINE;

ADULT; AGED; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PAIN; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

EID: 0030608237     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)02005-3     Document Type: Article

References (15)

1. 1 Medical Research Council Lung Cancer Working Party. Radiotherapy alone or with chemotherapy in the treatment of small-cell carcinoma of the lung. Br J Cancer 1979; 40: 1-10.
2. 2 Rawson NSB, Peto J. An overview of prognostic factors in small cell lung cancer: a report from the Subcommittee for the Management of Lung Cancer of the United Kindom Coordinating Committee on Cancer Research. Br J Cancer 1990; 61: 597-604.
3. 3 Ihde DC. Current status of therapy for carcinoma of the lung. Cancer 1984; 54: 2722-28.
4. 4 WHO. WHO Handbook for Reporting Results of Cancer Treatment. WHO offset publication no 48. Geneva: WHO, 1979.
5. 5 Slevin ML, Clark PI, Joel SP, et al. A randomised trial to evaluate the effects of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol 1989; 7: 1333-40.
6. 6 Clark PI, Joel SP, Slevin ML. A pharmacokinetic hypothesis for the clinical efficacy of etoposide in small cell lung cancer. Proc Am Soc Clin Oncol 1989; 8: 257.
7. 7 Harvey VJ, Slevin ML, Joel SP, Smythe MM, Johnston A, Wrigley PFM. Variable bioavailability following repeated oral doses of etoposide. Eur J Cancer Clin Oncol 1985; 21: 1315-19.
8. 8 Hande KR, Krozely MG, Greco FA, Hainsworth JD, Johnson DH. Bioavailability of low-dose oral etoposide. J Clin Oncol 1993; 11: 374-77.
9. 9 Clark PI, Cottier B. The activity of 10-, 14-, and 21-day schedules of single-agent etoposide in previously untreated patients with extensive SCLC. Semin Oncol 1992; 19 (suppl 14): 36-39.
10. 10 Dorward AJ, for the West of Scotland Lung Cancer Group. A prospective study of low dose oral etoposide in poor prognosis small cell lung cancer (SCLC). Lung Cancer 1991; 7 (suppl): 111, 409 (abstr).
11. 11 Medical Research Council Lung Cancer Working Party. Randomised trial of four-drug versus less intensive two-drug chemotherapy in the palliative treatment of patients with small cell lung cancer (SCLC) and poor prognosis. Br J Cancer 1996; 73: 406-13.
12. 12 Souhami RL, Tobias JS. Cancer and its management. Oxford: Blackwell Scientific Publications, 1986: 216.
13. 13 Machin D. Interim analysis and ethical issues in the conduct of trials. In: Williams CJ, ed. Introducing new treatments for cancer: practical, ethical, and legal problems. Chichester: John Wiley and Sons, 1992.
14. 14 Miller AA, Herndon JE II, Hollis DR, et al. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B. J Clin Oncol 1995; 13: 1871-79.
15. 15 Stephens RJ, Girling DJ, Machin D, for the Medical Research Council Lung Cancer Working Party. Treatment-related deaths in small cell lung cancer trials: can patients at risk be identified? Lung Cancer 1994; 11: 259-74.